NASDAQ
7.76USD
-0.70 (-8.31%)
We have scored 10 news catalysts on BioAge Labs Inc. (BIOA) over the past 12 months. The biggest single-day move next to one of them came Jan 12, 2026, when BIOA closed +27.2%: “BioAge Rockets As It Takes On Eli Lilly's Takeover Play, Ventyx Bio”. Coverage across the window leans positive (average ticker sentiment +0.67). Most of the impact sits in price momentum and short squeeze potential.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
292M
P/E
—
EPS
—
Beta
0.94
52W range
4.94-25.955
Day range
7.75–8.49
Open
8.43
Prev close
8.46
Volume
185.6K
Avg volume
770.7K
Dividend
0.00
IPO
2024-09-26
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about BioAge Labs Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for BIOA: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
BioAge Labs, Inc., a clinical-stage biopharmaceutical company, develops therapeutic product candidates for metabolic diseases. The company’s technology platform and differentiated human datasets that allows users to identify targets based on insights into molecular changes that drive aging. Its lead product candidate includes BGE-102, an orally available brain-penetrant small-molecule NLRP3 inhibitor which is in Phase 1 clinical trail for the treatment of atherosclerotic cardiovascular disease, as well as for the treatment of diabetic macular edema and geographic atrophy; and develops APJ agonists for obesity, including programs targeting both oral and parenteral administration. The company has collaboration agreement with Novartis Pharma AG to identify and validate novel therapeutic drug targets by investigating the biological mechanisms that drive diseases related to aging and mediate. BioAge Labs, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
